China Medical Group
Company Profile
China National Medical Group Co., Ltd. is an international pharmaceutical group company under the Wanquan Holding Group, a medical service group company under the Internet structure, and a leading provider of new medicine technology products and sales market services in China.
The group was evaluated as one of the five companies with great development potential in China by the Chinese edition of Fortune, the most authoritative international business magazine. The group has established abundant clinical terminal resources, grasped the historical opportunities of medical reform and the capital platform of Hong Kong, with mergers and acquisitions and medical professional management services as its core competitiveness, the group has built four professional platforms: the use of medical mobile platforms and hospital management under the Internet architecture The platform provides professional management services including trusteeship for Chinese hospitals; terminal clinical medical research promotion based on clinical research, the group will rely on extensive clinical registration research as a new product in one of the world’s largest medicine sales markets Listing and research provide a large number of research and promotion work; rehabilitation medical tourism platform, the group will invest in rehabilitation medical tourism products in Hainan, Xiamen and other places; specialty specialty hospital industry platform, the group will integrate specialty hospitals to create a nationwide specialty chain hospital. Enlighten mental rehabilitation, Haimer anti-aging and anti-intoxication field, Bymin allergy treatment, Demei Beauty DreamWorks and other fields provide professional integrated services of characteristic medical treatment. The Group continues to invest in enhancing its marketing capabilities and expanding its market network, launching a full-value chain new medicine technology development and value-added service business model in the local market under the Wanquan brand, and at the same time building and expanding overseas service markets under the VPS-CRO brand.
Development Path
In December 1998, Dezhong was established. On May 21, 2002, China National Medical Group Co., Ltd. was established. On December 21, 2002, Dezhong Wanquan began operations. In 2015, the Group provided a large number of post-marketing research and academic promotion services for the launch of new medicine and clinical trials. On February 19, 2016, the company’s wholly-owned subsidiary Beijing Wanquan Sunshine Medical Technology Co., Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. subsidiary Hunan Dongting Pharmaceutical Co., Ltd. signed a cooperation agreement.
Profit model
The company mainly provides contract clinical research services, post-market clinical research and academic promotion services. Contract clinical research services Contract clinical research services cover the entire clinical research process, including research design, volunteer recruitment, and phases of clinical research. In the first half of 2017, the company's contract clinical research service revenue was 4.671 million yuan. Post-marketing clinical research and academic promotion services Post-marketing drug clinical research is a clinical trial conducted after the medicine is approved for marketing. The purpose is to expand the understanding of the effectiveness of the marketed drug and confirm the safety of the drug for a wide range of people under actual use. In the first half of 2017, the company's post-IPO clinical research and academic promotion service revenue was 11.429 million yuan.
Company Name
China National Medical Group Co., Ltd. Time to market 2003-07-10 Official website http://www.chgi.net management team Guo Xia, Chairman of the Board CEO Guo Xia Chief Financial Officer Li Liang Listed exchange Hong Kong Stock Exchange Industry Medicine Address Haitong Business Center, No. 11 West Third Ring North Road, Haidian District, Beijing Largest shareholder Winsland Agents Limited